Drug Trial Radar · NCT03430284
Multifactorial Intervention on Diabetes (MIDiab Study)
Last checked: Nov 20, 2026Latest source record: Jul 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
6,300
Planned (sponsor's estimate)
Start
Apr 1, 2018
Primary completion
Dec 31, 2021
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Shandong Provincial HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- The Affiliated Hospital of Qingdao University; The First Hospital of Jilin University; The First People's Hospital of Yinchuan; Beijing Hospital, National Center of Gerontology; The First Affiliated Hospital of Air Force Medical University; Inner Mongolia People's Hospital; The Affiliated Hospital of Inner Mongolia Medical University; Fujian Medical University Union Hospital; The Fourth Affiliated Hospital of Harbin Medical University; Yantai Yuhuangding Hospital
- First posted
- Feb 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 35 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The prevalence of diabetes mellitus has been increasing in recent decades in China, and vascular complication is the major burden in patients with type 2 diabetes. Previous studies demonstrated that only glycemic control was not effective enough to prevent or improve diabetic vascular complications, but guidelines from the Chinese Diabetes Society and other national guidelines recommend an integrated multifactorial treatment approach. In this study, we aim to evaluate the effect on diabetic vascular complications of a multifactorial intervention comprising behavior modification, polypharmacological therapy and periodical monitoring in patients with type 2 diabetes.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Lifestyle therapyBehavioral
The key components of lifestyle therapy include medical nutrition therapy, regular physical activity, sufficient amounts of sleep, behavioral support, and smoking cessation and avoidance of all tobacco products.
PharmacotherapyDrug
Pharmacological therapy is individualized. 1.Glucose-lowering agents: 1. Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors 2. GLP-1 receptor agonist 3. Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products 2.Blood pressure-lowering agents (1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers 3.Lipid-modifying agents (1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc. 4.Medications for weight management (1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels.
Monitoring and managementOther
Before follow-up, patients are divided into low, moderate or high risk for diabetic vascular complications. During follow-up, frequencies of interview and risk factor monitoring are formulated based on the risk stratification.
General treatmentOther
General treatment is carried out based on the device from the general practitioners at present.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Integrated management rate of multiple risk factor in type 2 diabetesTime frame: 30 months
- Incidence of diabetic vascular complicationsTime frame: 30 months
- Control rate of diabetes and diabetic vascular complicationsTime frame: 30 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Shandong Provincial Hospital
Jinan, Shandong, China · Not yet recruiting
Shandong Provincial Hospital
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.